Foghorn therapeutics provides further update on fhd-286 phase i study in relapsed/refractory aml/mds

Cambridge, mass., aug. 23, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that the u.s. food and drug administration (fda) has placed a full clinical hold on the phase 1 dose escalation study of fhd-286, an inhibitor of brg1/brm, in relapsed and/or refractory acute myelogenous leukemia (aml) and myelodysplastic syndrome (mds). the dose escalation phase 1 study of fhd-286 in metastatic uveal melanoma (mum) continues per protocol. the company plans to report data from the mum study in the first half of 2023.
FHTX Ratings Summary
FHTX Quant Ranking